These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 37016200)

  • 1. Identification of EGFR inhibitors as potential agents for cancer therapy: pharmacophore-based modeling, molecular docking, and molecular dynamics investigations.
    Ashiru MA; Ogunyemi SO; Temionu OR; Ajibare AC; Cicero-Mfon NC; Ihekuna OA; Jagun MO; Abdulmumin L; Adisa QK; Asibor YE; Okorie CJ; Lawal MO; Babalola MO; Abdulrasaq IT; Salau LB; Olatunji IO; Bankole MA; Daud AB; Adeyemi AO
    J Mol Model; 2023 Apr; 29(5):128. PubMed ID: 37016200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of Novel EGFR Inhibitors for the Targeted Therapy of Colorectal Cancer Using Pharmacophore Modelling, Docking, Molecular Dynamic Simulation and Biological Activity Prediction.
    Krishnan K A; Valavi SG; Joy A
    Anticancer Agents Med Chem; 2024; 24(4):263-279. PubMed ID: 38173208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction and molecular dynamics simulation study of Osimertinib (AstraZeneca 9291) anticancer drug with the EGFR kinase domain in native protein and mutated L844V and C797S.
    Assadollahi V; Rashidieh B; Alasvand M; Abdolahi A; Lopez JA
    J Cell Biochem; 2019 Aug; 120(8):13046-13055. PubMed ID: 30916819
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Imana SN; Ningsih EG; Tambunan USF
    Pak J Biol Sci; 2020 Mar; 23(4):567-574. PubMed ID: 32363843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of the allosteric inhibitor from actinomyces metabolites to target EGFR
    Saini R; Kumari S; Bhatnagar A; Singh A; Mishra A
    Sci Rep; 2023 Jun; 13(1):8885. PubMed ID: 37264083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ligand-Based Pharmacophore Modeling, Molecular Docking, and Molecular Dynamic Studies of Dual Tyrosine Kinase Inhibitor of EGFR and VEGFR2.
    Sangande F; Julianti E; Tjahjono DH
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33096664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of potential edible spices as EGFR and EGFR mutant T790M/L858R inhibitors by structure-based virtual screening and molecular dynamics.
    Ahmad Ansari I; Debnath B; Kar S; Patel HM; Debnath S; Zaki MEA; Pal P
    J Biomol Struct Dyn; 2024 Mar; 42(5):2464-2481. PubMed ID: 37349948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. QSAR modeling, pharmacophore-based virtual screening, and ensemble docking insights into predicting potential epigallocatechin gallate (EGCG) analogs against epidermal growth factor receptor.
    Bommu UD; Konidala KK; Pabbaraju N; Yeguvapalli S
    J Recept Signal Transduct Res; 2019 Feb; 39(1):18-27. PubMed ID: 31223050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and exploration of quinazoline-1,2,3-triazole inhibitors targeting EGFR in lung cancer.
    Kumar S; Sengupta S; Ali I; Gupta MK; Lalhlenmawia H; Azizov S; Kumar D
    J Biomol Struct Dyn; 2023; 41(21):11353-11372. PubMed ID: 37114510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Search for potentially biased epidermal growth factor receptor (EGFR) inhibitors through pharmacophore modelling, molecular docking, and molecular dynamics (MD) simulation approaches.
    Jethwa M; Gangopadhyay A; Saha A
    J Biomol Struct Dyn; 2023 Mar; 41(5):1681-1689. PubMed ID: 35014597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Modeling, Docking, Dynamics and Simulation of Gefitinib and its Derivatives with EGFR in Non-small Cell Lung Cancer.
    Reddy PS; Lokhande KB; Nagar S; Reddy VD; Murthy PS; Swamy KV
    Curr Comput Aided Drug Des; 2018; 14(3):246-252. PubMed ID: 29493460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research.
    Dong RF; Zhu ML; Liu MM; Xu YT; Yuan LL; Bian J; Xia YZ; Kong LY
    Pharmacol Res; 2021 May; 167():105583. PubMed ID: 33775864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computational identification of new TKI as potential noncovalent reversible EGFR
    Abdelmalek D; Smaoui F; Frikha F; Ben Marzoug R; Msalbi D; Souissi A; Aifa MS
    J Biomol Struct Dyn; 2024 Jun; 42(9):4870-4887. PubMed ID: 37349947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular docking and dynamics studies of 4-anilino quinazolines for epidermal growth factor receptor tyrosine kinase to find potent inhibitor.
    Muthuvel SK; Elumalai E; K G; K H
    J Recept Signal Transduct Res; 2018; 38(5-6):475-483. PubMed ID: 31038021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies on ligand-based pharmacophore modeling approach in identifying potent future EGFR inhibitors.
    Shaikh GM; Murahari M; Thakur S; Kumar MS; Yc M
    J Mol Graph Model; 2022 May; 112():108114. PubMed ID: 34979367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacophore and molecular dynamics based activity profiling of natural products for kinases involved in lung cancer.
    Singh PK; Silakari O
    J Mol Model; 2018 Oct; 24(11):318. PubMed ID: 30343450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of luteolin -7-glucoside and epicatechin gallate from
    Maiti P; Nand M; Joshi T; Ramakrishnan MA; Chandra S
    J Biomol Struct Dyn; 2021 Sep; 39(14):5048-5057. PubMed ID: 32579072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In silico identification of EGFR-T790M inhibitors with novel scaffolds: start with extraction of common features.
    Xiang M; Lei K; Fan W; Lin Y; He G; Yang M; Chen L; Mo Y
    Drug Des Devel Ther; 2013; 7():789-839. PubMed ID: 23990708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of novel PI3Kδ inhibitors by docking, ADMET prediction and molecular dynamics simulations.
    Liu YY; Feng XY; Jia WQ; Jing Z; Xu WR; Cheng XC
    Comput Biol Chem; 2019 Feb; 78():190-204. PubMed ID: 30557817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.